Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 6/20 | 0.51 |
| ▸ | CTSS | P25774 | 5/20 | 0.51 |
| ▸ | CTSK | P43235 | 3/20 | 0.51 |
| ▸ | CTSB | P07858 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | FCER2 | P06734 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5520634 | 0.90 | CTSK (0.60) | CTSLCTSSCTSKCTSBEPHX1 | |
| SCHEMBL5520883 | 0.88 | MAPT (0.54) | MAPTEPHX1ALDH1A1CYP3A4GAA | |
| SCHEMBL5525396 | 0.87 | CTSL (0.50) | CTSLCTSSCTSKCTSBMAPT | |
| SCHEMBL5520633 | 0.84 | CPB2 (0.55) | CTSLCTSSCTSKCTSBALDH1A1 | |
| SCHEMBL5520892 | 0.83 | EPHX1 (0.52) | CTSLCTSSCTSKCTSBEPHX1 | |
| SCHEMBL5526359 | 0.83 | CTSK (0.60) | CTSLCTSSCTSKCTSB | |
| SCHEMBL5530376 | 0.79 | CTSK (0.58) | CTSLCTSSCTSKCTSB | |
| SCHEMBL5520618 | 0.78 | FPR2 (0.53) | CTSLCTSSCTSKCTSBALDH1A1 | |
| SCHEMBL5518458 | 0.78 | CTSS (0.53) | CTSLCTSSCTSKCTSBMAPT | |
| SCHEMBL5528697 | 0.78 | CTSK (0.57) | CTSLCTSSCTSKCTSBEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147503-A1 | Antiarthritic agents; muscular dystrophy; antiinflammatory agents; antitumor agents; glomerulonephritis | AXYS PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | claimed |
| US-20070232654-A1 | Novel Compounds and Compositions as Cathepsin Inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070232654-A1 | Novel Compounds and Compositions as Cathepsin Inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070232654-A1 | Novel Compounds and Compositions as Cathepsin Inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2007-10-04 | — | — | US | disclosed |
| US-20040147503-A1 | Antiarthritic agents; muscular dystrophy; antiinflammatory agents; antitumor agents; glomerulonephritis | AXYS PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232654-A1 | Novel Compounds and Compositions as Cathepsin Inhibitors | CTSS, CTSB, CTSE | CTSL 11/4885CTSS 1/4885CTSK 8/4885 |
| US-20040147503-A1 | Antiarthritic agents; muscular dystrophy; antiinflammatory agents; antitumor agents; glomerulonephritis | CAPNS1, CTSS, CTSV | CTSL 19/4885CTSS 2/4885CTSK 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.